Non Small cell Lung cancer(NSCLC) - Pipeline Review, 2019
FirstView Market Insight " Non Small cell Lung cancer(NSCLC)- Pipeline Review, 2019" provides an overview of the pipeline landscape. It provides comprehensive insights of all the clinical and non-clinical therapeutics in development with detailed description about the collaborations; deals; designations; patent information etc. These reports encourage the clients in distinguishing the upcoming and existing competitors in their separate therapeutic spaces. The report provides detailed description of the competitor profiles with key milestones and evidence along with analysis by mechanism of action; route of administration; molecule type; stage of development. Information obtained from multiple sources will be used to triangulate and update the profiles. The report also provides key events in the last year related to the indication. This report provides detailed analysis of all the products along with the companies involved.
Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). NSCLC accounts for about 85% of all lung cancers. As a class, NSCLCs are relatively insensitive to chemotherapy, compared to small cell carcinoma. Traditional chemotherapy has been the main treatment option in NSCLC. However, it is often associated with limited efficacy and overall poor patient survival. In recent years, molecular targeting has achieved great progress in therapeutic treatment of cancer and plays a crucial role in the current clinical treatment of NSCLC, due to enhanced efficacy on cancer tissues and reduced toxicity for normal tissues. The Global Non-Small Cell Lung Cancer Market is forecast to reach USD 10.53 Billion by 2027.
Generally, 5-year survival rate for lung cancer does not exceed 15%.Thus, novel treatment strategies based on targeted therapy and targeted compounds started to be developed and implemented by researchers and clinicians. For patients with advanced non-small-cell lung cancer (nsclc) lacking a targetable molecular driver, the mainstay of treatment has been cytotoxic chemotherapy. The survival benefit of chemotherapy in this setting is modest and comes with the potential for significant toxicity. The introduction of immunotherapeutic agents targeting the programmed cell death 1 protein (PD-1) and the programmed cell death ligand 1 (PD-L1) has drastically changed the treatment paradigms for these patients. Three agents—atezolizumab, nivolumab, and pembrolizumab—have been shown to be superior to chemotherapy in the second-line setting.
Report Overview:
This part of report provides detailed description of indication which enables the client to understand the landscape of the Non small cell lung cancer disease. This report covers the basic definition, etiology, symptoms, disease progression, treatment guidelines, pathophysiology, methods to diagnose for Non small cell lung cancer disease.
Pipeline Overview:
This report provides extensive scenario and growth prospects of the market. This section includes the graphical representations of the future treatment landscape based on various phases of development including the NDA/BLA Filing, Phase III, Phase II, Phase I, Pre-Clinical and the Discovery. It also includes details of products which have been dormant or discontinued during the trial stages of development.
Drug Profile Overview:
The pipeline section provides descriptive drug profiles for the pipeline products including product description, mechanism of action, route of administration, molecule type, technology involved, chemical information.
Clinical Trial Overview:
This section of the report focuses on the clinical activity of the molecule. It includes both clinical and pre-clinical activity which provides detailed information about the safety, efficacy, tolerability, toxicity of pipeline drugs. A graphical representation of the clinical trial landscape of pipeline therapy which includes information about phase of development, trial design, treatment arms, dosage and frequency, formulation of the drug, primary and secondary completion date, enrolment number, exclusion and inclusion criteria, line of therapy. This section also includes the clinical trial results and analysis based on those results.
Product Development Activity:
This section of the report focuses on detail information about designations, exclusivity details, technology, licensing and collaboration, funding and financing, key milestones and various other development activities.
Company Overview:
Company profile includes the detail about type of company, headquarter, global presence, research focus and key financial
Scope
Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). NSCLC accounts for about 85% of all lung cancers. As a class, NSCLCs are relatively insensitive to chemotherapy, compared to small cell carcinoma. Traditional chemotherapy has been the main treatment option in NSCLC. However, it is often associated with limited efficacy and overall poor patient survival. In recent years, molecular targeting has achieved great progress in therapeutic treatment of cancer and plays a crucial role in the current clinical treatment of NSCLC, due to enhanced efficacy on cancer tissues and reduced toxicity for normal tissues. The Global Non-Small Cell Lung Cancer Market is forecast to reach USD 10.53 Billion by 2027.
Generally, 5-year survival rate for lung cancer does not exceed 15%.Thus, novel treatment strategies based on targeted therapy and targeted compounds started to be developed and implemented by researchers and clinicians. For patients with advanced non-small-cell lung cancer (nsclc) lacking a targetable molecular driver, the mainstay of treatment has been cytotoxic chemotherapy. The survival benefit of chemotherapy in this setting is modest and comes with the potential for significant toxicity. The introduction of immunotherapeutic agents targeting the programmed cell death 1 protein (PD-1) and the programmed cell death ligand 1 (PD-L1) has drastically changed the treatment paradigms for these patients. Three agents—atezolizumab, nivolumab, and pembrolizumab—have been shown to be superior to chemotherapy in the second-line setting.
Report Overview:
This part of report provides detailed description of indication which enables the client to understand the landscape of the Non small cell lung cancer disease. This report covers the basic definition, etiology, symptoms, disease progression, treatment guidelines, pathophysiology, methods to diagnose for Non small cell lung cancer disease.
Pipeline Overview:
This report provides extensive scenario and growth prospects of the market. This section includes the graphical representations of the future treatment landscape based on various phases of development including the NDA/BLA Filing, Phase III, Phase II, Phase I, Pre-Clinical and the Discovery. It also includes details of products which have been dormant or discontinued during the trial stages of development.
Drug Profile Overview:
The pipeline section provides descriptive drug profiles for the pipeline products including product description, mechanism of action, route of administration, molecule type, technology involved, chemical information.
Clinical Trial Overview:
This section of the report focuses on the clinical activity of the molecule. It includes both clinical and pre-clinical activity which provides detailed information about the safety, efficacy, tolerability, toxicity of pipeline drugs. A graphical representation of the clinical trial landscape of pipeline therapy which includes information about phase of development, trial design, treatment arms, dosage and frequency, formulation of the drug, primary and secondary completion date, enrolment number, exclusion and inclusion criteria, line of therapy. This section also includes the clinical trial results and analysis based on those results.
Product Development Activity:
This section of the report focuses on detail information about designations, exclusivity details, technology, licensing and collaboration, funding and financing, key milestones and various other development activities.
Company Overview:
Company profile includes the detail about type of company, headquarter, global presence, research focus and key financial
Scope
- The report provides a competitive landscape of Non small cell lung cancer
- The report also provides clinical trial landscape of the pipeline drugs including status; trial phase; sponsor type and end-point status
- The report provides the list of companies which are the most active in the pipeline
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery
- The report provides descriptive drug profiles which includes product description; comprising detailed mechanism of action (MoA); route of administration (RoA); Stage of development; clinical trial status; licensing and collaboration details & other developmental activities
- The report features comparative analysis of product profiles based on molecule type; mechanism of action (MoA); route of administration (RoA)
- The report summarizes all the dormant and discontinued pipeline projects
- The report also provides latest news for the past one year
- To identifying prominent players in the Non small cell lung cancer treatment landscape
- To determine the drivers; barriers and unmet need in the Non small cell lung cancer treatment space
- Gain strategically significant competitor information; analysis; and insights to formulate effective R&D strategies
- Define in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- To understand the composition of the pipeline in terms of molecule type; molecular target; mechanism of action and route of administration
1. DISEASE OVERIEW
1.1. Pathophysiology
1.2. Symptoms
1.3. Etiology
1.4. Diagnosis
1.5. Treatment Algorithm
1.6. Treatment Option:
1.7. Classification or Staging Systems
2. FEATURED NEWS AND PRESS RELEASES, 2018-2019
3. NON-SMALL CELL LUNG CANCER MOLECULAR TARGET EVALUATION
3.1. Epidermal growth factor receptor (EGFR)
3.2. Phosphatidylinositol 3-kinase (PI3Ks)
3.3. Mechanistic target of rapamycin (mTOR)
3.4. Epidermal growth factor receptor 2 (ErbB2)
3.5. Vascular epidermal growth factor receptor (VEGFR)
3.6. Kirsten human rat sarcoma protein (KRAS)
3.7. Mesenchymal-epithelial transition factor or hepatocyte growth factor receptor (c-MET), Anaplastic lymphoma kinase (ALK)
3.8. v-Raf murine sarcoma viral oncogene homolog B (BRAF)
4. LIST OF COMPANIES DEVELOPING NON-SMALL CELL LUNG CANCER(NSCLC)- PIPELINE REVIEW, 2019
5. PIPELINE THERAPEUTICS
6. THERAPEUTICS UNDER DEVELOPMENT BY COMPANIES
7. LATE STAGE PRODUCTS (FILED & PHASE III)
7.1. Dacomitinib – Filed
7.1.1. Product Description
7.1.2. Research and Development
7.1.3. Product Development Activities
7.2. Capmatinib – Phase III
7.2.1. Product Description
7.2.2. Research and Development
7.2.3. Product Development Activities
7.3. Nazartinib – Phase III
7.3.1. Product Description
7.3.2. Research and Development
7.3.3. Product Development Activities
8. MID STAGE PRODUCTS (PHASE II)
8.1. ATL 001 – Phase I/II
8.1.1. Product Description
8.1.2. Research and Development
8.1.3. Product Development Activities
8.2. SLATE 001 – Phase I/II
8.2.1. Product Description
8.2.2. Research and Development
8.2.3. Product Development Activities
8.3. CBP 501-Phase II
8.3.1. Product Description
8.3.2. Research and Development
8.3.3. Product Development Activities
8.4. Cositecan: Phase II
8.4.1. Product Description
8.4.2. Research and Development
8.4.3. Product Development Activities
9. EARLY STAGE PRODUCTS (PHASE I AND IND)
9.1. FCN 411: Phase I
9.1.1. Product Description
9.1.2. Research and Development
9.1.3. Product Development Activities
9.2. Teleukin - Phase I
9.2.1. Product Description
9.2.2. Research and Development
9.2.3. Product Development Activities
10. DRIVERS OF NON SMALL CELL LUNG CANCER(NSCLC)- PIPELINE REVIEW, 2019
11. CONSTRAINTS OF NON SMALL CELL LUNG CANCER(NSCLC)- PIPELINE REVIEW, 2019
12. THERAPEUTIC ASSESSMENT
12.1. Assessment by Route of Administration
12.2. Assessment by Phase & Route of Administration
12.3. Assessment by Molecule Type
12.4. Assessment by Phase & Molecule type
12.5. Assessment by Target
12.6. Assessment by Mechanism of Action
13. COLLABORATIONS AND ACQUISITIONS DETAILS
14. DORMANT PRODUCTS
15. DISCONTINUED PRODUCTS
16. MARKET TRENDS
17. MARKET OPPORTUNITY ASSESSMENT
18. UNMET NEEDS
19. SWOT ANALYSIS
20. APPENDIX
21. REPORT METHODOLOGY
22. CONSULTING SERVICES
23. DISCLAIMER
1.1. Pathophysiology
1.2. Symptoms
1.3. Etiology
1.4. Diagnosis
1.5. Treatment Algorithm
1.6. Treatment Option:
1.7. Classification or Staging Systems
2. FEATURED NEWS AND PRESS RELEASES, 2018-2019
3. NON-SMALL CELL LUNG CANCER MOLECULAR TARGET EVALUATION
3.1. Epidermal growth factor receptor (EGFR)
3.2. Phosphatidylinositol 3-kinase (PI3Ks)
3.3. Mechanistic target of rapamycin (mTOR)
3.4. Epidermal growth factor receptor 2 (ErbB2)
3.5. Vascular epidermal growth factor receptor (VEGFR)
3.6. Kirsten human rat sarcoma protein (KRAS)
3.7. Mesenchymal-epithelial transition factor or hepatocyte growth factor receptor (c-MET), Anaplastic lymphoma kinase (ALK)
3.8. v-Raf murine sarcoma viral oncogene homolog B (BRAF)
4. LIST OF COMPANIES DEVELOPING NON-SMALL CELL LUNG CANCER(NSCLC)- PIPELINE REVIEW, 2019
5. PIPELINE THERAPEUTICS
6. THERAPEUTICS UNDER DEVELOPMENT BY COMPANIES
7. LATE STAGE PRODUCTS (FILED & PHASE III)
7.1. Dacomitinib – Filed
7.1.1. Product Description
7.1.2. Research and Development
7.1.3. Product Development Activities
7.2. Capmatinib – Phase III
7.2.1. Product Description
7.2.2. Research and Development
7.2.3. Product Development Activities
7.3. Nazartinib – Phase III
7.3.1. Product Description
7.3.2. Research and Development
7.3.3. Product Development Activities
8. MID STAGE PRODUCTS (PHASE II)
8.1. ATL 001 – Phase I/II
8.1.1. Product Description
8.1.2. Research and Development
8.1.3. Product Development Activities
8.2. SLATE 001 – Phase I/II
8.2.1. Product Description
8.2.2. Research and Development
8.2.3. Product Development Activities
8.3. CBP 501-Phase II
8.3.1. Product Description
8.3.2. Research and Development
8.3.3. Product Development Activities
8.4. Cositecan: Phase II
8.4.1. Product Description
8.4.2. Research and Development
8.4.3. Product Development Activities
9. EARLY STAGE PRODUCTS (PHASE I AND IND)
9.1. FCN 411: Phase I
9.1.1. Product Description
9.1.2. Research and Development
9.1.3. Product Development Activities
9.2. Teleukin - Phase I
9.2.1. Product Description
9.2.2. Research and Development
9.2.3. Product Development Activities
10. DRIVERS OF NON SMALL CELL LUNG CANCER(NSCLC)- PIPELINE REVIEW, 2019
11. CONSTRAINTS OF NON SMALL CELL LUNG CANCER(NSCLC)- PIPELINE REVIEW, 2019
12. THERAPEUTIC ASSESSMENT
12.1. Assessment by Route of Administration
12.2. Assessment by Phase & Route of Administration
12.3. Assessment by Molecule Type
12.4. Assessment by Phase & Molecule type
12.5. Assessment by Target
12.6. Assessment by Mechanism of Action
13. COLLABORATIONS AND ACQUISITIONS DETAILS
14. DORMANT PRODUCTS
15. DISCONTINUED PRODUCTS
16. MARKET TRENDS
17. MARKET OPPORTUNITY ASSESSMENT
18. UNMET NEEDS
19. SWOT ANALYSIS
20. APPENDIX
21. REPORT METHODOLOGY
22. CONSULTING SERVICES
23. DISCLAIMER
LIST OF TABLES
Table 1: Marketed and Pipeline Non Small cell Lung cancer(NSCLC)- Pipeline Review, 2019 drugs, 2019
Table 2: Sales of Marketed drugs, 2019
Table 3: Patent expiration details – marketed drugs, 2019
Table 4: Number of Products Under Development for Non Small cell Lung cancer(NSCLC)- Pipeline Review, 2019, 2019
Table 5: Products under Development by Companies, 2019
Table 6: Late Stage Products, 2019
Table 7: Mid Stage Products, 2019
Table 8: Early Stage Products, 2019
Table 9: Pre-Clinical and Discovery Products, 2019
Table 10: Assessment by Route of Administration, 2019
Table 11: Assessment by Stage and Route of Administration, 2019
Table 12: Assessment by Molecule Type, 2019
Table 13: Assessment by Stage and Molecule Type, 2019
Table 14: Assessment by Target, 2019
Table 15: Assessment by Mechanism of Action, 2019
Table 16: Dormant Products, 2019
Table 17: Discontinued Products, 2019
Table 1: Marketed and Pipeline Non Small cell Lung cancer(NSCLC)- Pipeline Review, 2019 drugs, 2019
Table 2: Sales of Marketed drugs, 2019
Table 3: Patent expiration details – marketed drugs, 2019
Table 4: Number of Products Under Development for Non Small cell Lung cancer(NSCLC)- Pipeline Review, 2019, 2019
Table 5: Products under Development by Companies, 2019
Table 6: Late Stage Products, 2019
Table 7: Mid Stage Products, 2019
Table 8: Early Stage Products, 2019
Table 9: Pre-Clinical and Discovery Products, 2019
Table 10: Assessment by Route of Administration, 2019
Table 11: Assessment by Stage and Route of Administration, 2019
Table 12: Assessment by Molecule Type, 2019
Table 13: Assessment by Stage and Molecule Type, 2019
Table 14: Assessment by Target, 2019
Table 15: Assessment by Mechanism of Action, 2019
Table 16: Dormant Products, 2019
Table 17: Discontinued Products, 2019
LIST OF FIGURES
Figure 1: Marketed and Pipeline Non Small cell Lung cancer(NSCLC)- Pipeline Review, 2019 drugs, 2019
Figure 2: Sales of Marketed drugs, 2019
Figure 3: Patent expiration details – marketed drugs, 2019
Figure 4: Number of Products Under Development for Non Small cell Lung cancer(NSCLC)- Pipeline Review, 2019, 2019
Figure 5: Products under Development by Companies, 2019
Figure 6: Late Stage Products, 2019
Figure 7: Mid Stage Products, 2019
Figure 8: Early Stage Products, 2019
Figure 9: Pre-Clinical and Discovery Products, 2019
Figure 10: Assessment by Route of Administration, 2019
Figure 11: Assessment by Stage and Route of Administration, 2019
Figure 12: Assessment by Molecule Type, 2019
Figure 13: Assessment by Stage and Molecule Type, 2019
Figure 14: Assessment by Target, 2019
Figure 15: Assessment by Mechanism of Action, 2019
Figure 16: Dormant Products, 2019
Figure 17: Discontinued Products, 2019
Figure 1: Marketed and Pipeline Non Small cell Lung cancer(NSCLC)- Pipeline Review, 2019 drugs, 2019
Figure 2: Sales of Marketed drugs, 2019
Figure 3: Patent expiration details – marketed drugs, 2019
Figure 4: Number of Products Under Development for Non Small cell Lung cancer(NSCLC)- Pipeline Review, 2019, 2019
Figure 5: Products under Development by Companies, 2019
Figure 6: Late Stage Products, 2019
Figure 7: Mid Stage Products, 2019
Figure 8: Early Stage Products, 2019
Figure 9: Pre-Clinical and Discovery Products, 2019
Figure 10: Assessment by Route of Administration, 2019
Figure 11: Assessment by Stage and Route of Administration, 2019
Figure 12: Assessment by Molecule Type, 2019
Figure 13: Assessment by Stage and Molecule Type, 2019
Figure 14: Assessment by Target, 2019
Figure 15: Assessment by Mechanism of Action, 2019
Figure 16: Dormant Products, 2019
Figure 17: Discontinued Products, 2019
